 | 
|
| |
|
Titel: Biologisk ingenjörskonst ger ny astmaterapi (serie: Tema immunterapi vid astma/allergi) 2008 nr 26 sid 1942-5
|
Referenser:
1.Chapman MD, Pomés A, Breiteneder H, Ferreira F Nomenclature and structural biology of allergens. J Allergy Clin Immunol. 2007;119:414-20.
2.Kaiser L, Cirkovic Velickovic T, Badia-Martinez D, Adedoyin J, Thunberg S, Hallén D, Berndt K, Grönlund H, Gafvelin G, van Hage M, Achour A. Structural characterization of the tetrameric form of the major cat allergen Fel d 1. J Mol Biol. 2007;20;370:714-27.
3.Valenta R, Niederberger V. Recombinant allergens for immunotherapy. J Allergy Clin Immunol. 2007;119:826-30. Review.
4.http://www.ncbi.nlm.nih.gov/pubmed/17010585?ordinalpos=3&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSumCrameri R, Rhyner . Novel vaccines and adjuvants for allergen-specific immunotherapy. Curr Opin Immunol. 2006;18:761-8. Review.
5.Niederberger V, Horak F, Vrtala S, Spitzauer S, Krauth MT, Valent P, Reisinger J, Pelzmann M, Hayek B, Kronqvist M, Gafvelin G, Grönlund H, Purohit A, Suck R, Fiebig H, Cromwell O, Pauli G, van Hage-Hamsten M, Valenta R. Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci U S A. 2004;101 Suppl 2:14677-82.
6.van Hage-Hamsten M, Kronqvist M, Zetterström O, Johansson E, Niederberger V, Vrtala S, Grönlund H, Grönneberg R, Valenta R. Skin test evaluation of genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1: Results obtained with a mix of recombinant Bet v 1 fragments and recombinant Bet v 1 trimer in a Swedish population before the birch pollen season. J Allergy Clin Immunol 1999;104:969-77.
7.Pauli G, Purohit A, Oster JP, De Blay F, Vrtala S, Niederberger V, Kraft D, Valenta R. Comparison of genetically engineered hypoallergenic rBet v 1 derivatives with rBet v 1 wild-type by skin prick and intradermal testing: results obtained in a French population. Clin Exp Allergy. 2000;30:1076-84.
8.van Hage-Hamsten M, Johansson E, Roquet A, Peterson C, Andersson M, Greiff L, Vrtala S, Valenta R, Grönneberg R. Nasal challenges with recombinant derivatives of the major birch pollen allergen Bet v 1 induce fewer symptoms and lower mediator release than rBet v 1 wild-type in patients with allergic rhinitis. Clin Exp Allergy 2002;32:1448-53.
9.Reisinger J, Horak F, Pauli G, van Hage M, Cromwell O, König F, Valenta R, Niederberger V. Allergen-specific nasal IgG induced by vaccination with genetically modified allergens are associated with reduced nasal allergen sensitivity. J Allergy Clin Immunol 2005;116:347-54.
10.Gafvelin G, Thunberg S, Kronqvist M, Grönlund H, Grönneberg R, Troye-Blomberg M, Akdis M, Fiebig H, Purohit A, Horak F, Reisinger J, Niederberger V, Akdis CA, Cromwell O, Pauli G, Valenta R, van Hage M. Cytokine and antibody responses in birch-pollen-allergic patients treated with genetically modified derivatives of the major birch pollen allergen Bet v 1. Int Arch Allergy Immunol 2005;138:59-66.
11.Niederberger V, Reisinger J, Valent P, Krauth MT, Pauli G, van Hage M, Cromwell O, Horak F, Valenta R. Vaccination with genetically modified birch pollen allergens: Immune and clinical effects on oral allergy syndrome. J Allergy Clin Immunol. 2007;119:1013-6.
12.Kahlert H, Suck R, Weber B, Nandy A, Wald M, Keller W, Cromwell O, Fiebig H. Characterization of a Hypoallergenic Recombinant Bet v 1 Variant as a Candidate for Allergen-Specific Immunotherapy. Int Arch Allergy Immunol. 2008;145:193-206.
13.Kettner J, Meyer H, Cromwell O, Narkus A, Jost K. Specific immunotherapy with recombinant birch pollen allergen rBet v 1-FV results of 2 years of treatment (Phase II trial). Allergy 2007;62 (Suppl. 83):262.
14.Jutel M, Jaeger L, Suck R, Meyer H, Fiebig H, Cromwell O. Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol. 2005;116:608-13.
15.Pauli G, Malling J, Rak S, Horak F, Pastorello E, Purohit A, Holst-Larsen T, Arvidsson M, Mothes N, Kavina A, Szaal S, Schroeder J, Vighi G, Valenta R, Montagut A, Galvain S, Mélac M, André C. Subcutaneous immunotherapy with recombinant Bet v 1 in birch allergy: clinical and immunological effects. Allergy 2007;62 (Suppl. 83):256.
16.Simons FE, Shikishima Y, Van Nest G, Eiden JJ, HayGlass KT: Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA. J Allergy Clin Immunol 2004;113:1144-51.
17.Creticos PS, Schroeder JT, Hamilton RG, Balcer-Whaley SL, Khattignavong AP, Lindblad R, Li H, Coffman R, Seyfert V, Eiden JJ, Broide D: Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 2006;355:1445-55.
18.Drachenberg KJ, Wheeler AW, Stuebner P, Horak F: A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy 2001;56:498-505.
19.Mothes N, Heinzkill M, Drachenberg KJ, Sperr WR, Krauth MT, Majlesi Y, Semper H, Valent P, Niederberger V, Kraft D, Valenta R: Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin Exp Allergy 2003;33:1198-208.
20.Puggioni F, Durham SR, Francis JN: Monophosphoryl lipid A (MPL) promotes allergen-induced immune deviation in favour of Th1 responses. Allergy 2005;60:678-84.
21.Kündig TM, Senti G, Schnetzler G, Wolf C, Prinz Vavricka BM, Fulurija A, Hennecke F, Sladko K, Jennings GT, Bachmann MF: Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults. J Allergy Clin Immunol 2006;117:1470-6.
22.Zhu D, Kepley CL, Zhang K, Terada T, Yamada T, Saxon A: A chimeric human-cat fusion protein blocks cat-induced allergy. Nat Med 2005;11:446-9.
23.Larche M. Peptide immunotherapy for allergic diseases. Allergy 2007; 62:325-31.
24.Norman PS, Ohman JL Jr, Long AA, Creticos PS, Gefter MA, Shaked Z, Wood RA, Eggleston PA, Hafner KB, Rao P, Lichtenstein LM, Jones NH, Nicodemus CF. Treatment of cat allergy with T-cell reactive peptides. Am J Respir Crit Care Med 1996; 154: 1623-28.
25.Simons FE, Imada M, Li Y, Watson, WT, HayGlass KT: Fel d 1 peptides: effect on skin tests and cytokine synthesis in cat-alergic human subjects. Int Immunology 1996; 8: 1937-45.
26.Maguire P, Nicodemus C, Robinson D, Aaronson D, Umetsu DT The safety and efficacy of ALLERGVAX CAT in cat allergic patients. Clin Immunol. 1999; 93:222-31.
27.Oldfield WL, Larche M, Kay AB: Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. Lancet 2002; 360: 47-53.
28.AlexanderC, Tarzi M, Larche M, Kay AB: The effect of Fel d 1-derived T-cell peptides on upper and lower airway outcome measurements in cat-allergic subjects. Allergy 2005; 60:1269-74.
29.Müller U, Akdis CA, Fricker M, Akdis M, Blesken T, Bettens F, Blaser K: Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol 1998; 101:747-54.
30.Tarzi M, Klunker S, Texier C, Verhoef A, Stapel SO, Akdis CA, Mailere B, Kay AB, Larche M: Induction of interleukin-10 and suppressor of cytokine signalling-3 gene expression following peptide immunotherapy. Clin Exp Allergy 2006; 36: 465-74.
31.Fellrath JM, Kettner A, Dufour N, Frigerio C, Schneeberger D, Leimgruber A, Corradin G, Spertini F. Allergen-specific T-cell tolerance induction with allergen-derived long synthetic peptides: results of a phase I trial, J Allergy Clin Immunol 2003; 111: 854-861.
32.Gupta RK, Siber GR. Adjuvants for human vaccines--current status, problems and future prospects. Vaccine 1995;13:1263-76.
33.Grönlund H, Vrtala S, Wiedermann U, Dekan G, Kraft D, Valenta R, van Hage-Hamsten M. Carbohydrate-based particles: a new adjuvant for allergen-specific immunotherapy. Immunology 2002;107:523-9.
34.Andersson TN, Ekman GJ, Grönlund H, Buentke E, Eriksson TL, Scheynius A, Van Hage-Hamsten M, Gafvelin G. A novel adjuvant-allergen complex, CBP-rFel d 1, induces up-regulation of CD86 expression and enhances cytokine release by human dendritic cells in vitro. Immunology 2004;113:253-9.
35.Ewbank PA, Murray J, Sanders K, Curran-Everett D, Dreskin S, Nelson HS. A double-blind, placebo-controlled immunotherapy dose-response study with standardized cat extract. J Allergy Clin Immunol 2003;111:155-61.
36. Neimert-Andersson T, Thunberg S, Swedin L, Wiedermann U, Jacobsson-Ekman G, Dahlén S-E, Scheynius A, Grönlund H, van Hage M, Gafvelin G. Carbohydrate-based particles reduce allergic inflammation in a mouse model for cat allergy. Accepted for publication in Allergy.
37.Senti G, Prinz-Vavricka, Erdmann I, Diaz M, Markus R, McCormack S, Crameri R, Akdis C, Wütrich B, Graf N, Johansen P, Kündig T. Intralymphatic allergen administration renders specific immunotherapy shorter and safer. Allergy 2007;62 (Suppl. 83):34.
38.Crameri R, Fluckiger S, Daigle I, Kündig T, Rhyner C. Design, engineering and in vitro evaluation of MHC class-II targeting allergy vaccines. Allergy 2007;62(2):197-206.
 1942 |
 1943 |
 1944 |
 1945 |